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Background: Alpha-1-antitrypsin deficiency (AATD) is significantly underdiagnosed. The
early detection of AATD would enable affected persons to make lifestyle changes such as
quitting smoking. It was the aim of the study to determine whether the combination of an
awareness program with the offer of a cost-free diagnostic test results in the identification
of a significant number of individuals with severe AATD.
Methodology: We combined a series of measures to promote awareness with the offer of a
diagnostic test at no charge. Test blood was applied to a filter paper and sent to our
laboratory. The level of AAT was measured by nephelometry, the presence of the S- or Z-
allele was determined by PCR, and phenotyping was performed by isoelectric focusing.
Results: During 37 months 17 688 testing kits were distributed and 2722 were sent back to
our laboratory. We identified 335 patients with severe AATD including 16 individuals with
rare genotypes. Prescreening by determining the AAT serum levels by the submitting
physician increased the detection rate as compared to similar programs that screened
unselected individuals.
Summary: These data show that the combination of an awareness program with the offer
of free diagnostic testing results in the identification of a large number individuals with
severe AATD.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
1 286 4994; fax +49 6421 286 8987.
burg.de (R. Bals).
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Alpha-1-antitrypsin deficiency (AATD) is caused by mutations
of the SERPINA1 (formerly known as PI) gene and can result
in two clinically relevant manifestations.1 Development of
liver disease in early childhood and adulthood potentially
results in liver cirrhosis. Adults with severe AATD have a high
risk of developing early chronic obstructive pulmonary
disease (COPD) with smoking being the most important
additional risk factor. AATD is the only known monogenic
genetic risk factor for the development of COPD. Population
based studies indicate that the frequency of the ZZ
genotype is between one in 1639 and 5097 in the general
population.2–4
The percentage of COPD patients with severe AATD has
been investigated in several studies and found in between
less than 0.1% and 17.8% of cases.5 The differences likely
depend on the study population enrolled in the analysis. It is
estimated that in Germany, other European countries, and
the USA less than 10% of the expected homozygous PiZ
(presence of the Z-allele in a homozygous constellation)
individuals have been identified so far.4 It is not clear
whether the unidentified individuals are free of symptoms
and clinical signs or simply not diagnosed. The vast majority
of known patients with AATD is diagnosed after the onset of
liver or lung disease. The delay between the onset of
symptoms and the diagnosis is a continuing problem.6 Early
detection of AATD would allow reduction of the risk for
development or deterioration of the disease by adequate
counseling including advice for smoking cessation. Knowl-
edge of an inheritable disease could also result in the
detection of family members with this genetic predisposi-
tion resulting in lifestyle changes. For patients with AATD-
caused COPD, the substitution of AAT is a therapeutic option
albeit so far no efficacy data from a randomized trial is
available.7
Factors that limit the identification of individuals with
AATD are manifold. The condition is rare, therefore, the
majority of physicians is not familiar with the symptoms and
the diagnostic steps. The diagnostic tests are not readily
available and genotyping and phenotyping are expensive.
Guidelines state that testing is indicated for individuals with
certain conditions. A report of the World Health Organiza-
tion (WHO) recommends the establishment of screening
programs and that patients with COPD should be tested.8
The recent guidelines of the American Thoracic Society
(ATS) and the European Respiratory Society (ERS) for the
management of patients with AATD outlines detailed
recommendations.5
Several programs have been established to identify
individuals with AATD. A recent case-detection pro-
gram used the combination of protein quantification and
genetic testing to screen for AATD patients in a group of
2137 COPD patients and was able to detect eight individuals
with PiZZ.9 No individuals with severe AATD could be
detected in a screening program enrolling 1060 COPD
patients.10
The aim of the retrospective analysis was to investigate
whether the combination of a program to increase aware-
ness with the offer of an easily accessible and cost-free test
would result in a significant number of detected persons
with AATD.Methods
The present study analyzes the results of a diagnostic
service with the aim to detect individuals with AATD. The
diagnostic service is combined with measures to increase
awareness of physicians. This service is sponsored by the
Hospital of the Universities of Giessen and Marburg and
Bayer Health Care, Germany. The awareness activities are
run by the agency Konsens (Werne, Germany) that is funded
by Bayer Healthcare. All parts of the program were planned
together and are documented by appropriate contracts. We
require that the blood for testing is obtained by a physician
and that the tested person is informed about the meaning
and potential consequences of the test and its outcome.
Written consent from the tested individual or of the legal
representative is required. The retrospective analysis was
approved by the Ethical Committee of the University of
Marburg. The analysis period is from August 2003 to August
2006.
Awareness program
Low awareness of AATD and its symptoms might be an
important limiting factor for the detection of individuals
with this genetic predisposition. We started an awareness
campaign with the following elements:1. Distribution of information material to all pulmonary and
pediatric specialists and to general practitioners in
Germany. This material consisted of a letter to the
physician, a brochure about AATD and a form to request
the testing kit. The brochure provided information about
AATD (natural history, pathophysiology), typical symp-
toms and clinical constellations, indications for testing, a
description of the diagnostic approach (initial measure-
ment of the serum level, followed by further diagnostic
testing with the offered test kit if low levels of serum AAT
are present or if the clinical situation is suggestive of
AATD) and resources for further information.2. Installation of information in the WWW at the website of
the University of Marburg (URL: http://www.med.uni-
marburg.de) and on a specific website (URL: http://
www.alphakit.de, http://www.alpha-1-info.com, http://
www.alpha-1-register.de).3. Offering information material at national scientific
meetings.4. Inclusion of information in lectures at national medical
and scientific pulmonary meetings.
The activities to increase awareness are displayed in Table 1
in a chronological order.
Testing material
The test kit consists of an instruction manual that outlines
the purpose of the testing and the procedure how to obtain a
blood specimen. Blood is applied to a filter paper, dried and
shipped to our laboratory at the University of Marburg. Dried
blood samples on filter papers have been used for screening
and testing for AATD earlier.10,11 The filter paper includes a
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Table 1 Summary of measurements to increase physicians’ awareness for AATD.
Activity to increase awareness Time point Reference for Fig 1
Mailing to pulmonologists (865 letters) 10/2003 1
Mailing to pulmonologists (900) and pediaticians (6,000) 2/2004 2
Mailing to general practitioners (70,000) 6/2004 3
R. Bals et al.1710text field for patient identification, for the address of the
physician, and for a signature of the patient.Nephelometry
IEF
Clear results from 
PCR and IEF ? **
No
Yes
Yes
No
Testing Kits
Database 
Registration
Quality control
PCR 
for Z - or S - allel
Evidence for
AATD by either test * 
Report
Gene Sequencing
Figure 1 Flow chart explaining the testing procedure. * If the
were indications for the presence of AATD in the PCR (presence of
Z- or S-allele) or in the nephelometry (content below a threshold)
an IEF was performed. The PCR analysis of 2696 samples revealed
876 abnormal results (presence of Z- or S-allele). ** If there were
indications for the presence of a rare genotype (unusual IEF
pattern, low level of AAT in nephelometry) the exons of SERPINA1
were sequenced. A total number of 1048 sampled revealed a low
content of AAT in the filter by nephelometry. A total number of
1200 samples were subjected to IEF. A total number of 21
samples were analyzed by sequencing and 13 individuals with
rare genotypes were identified. The report to the physician
contained the results of the PCR, the IEF, and the gene
sequencing. The nephelometry data were not reported.Testing procedure
The analysis of the testing material was performed at the
University of Marburg. The data were inserted in a Microsoft
Access based database system. If the amount of blood was
too low for the testing procedure the physician was asked to
provide more material. All samples were processed for the
quantification of the AAT amount in the filter paper and for
the presence of the S- or the Z-allele. If there were
indications for the presence of a genetic alteration in the
AAT-gene the sample was processed by isoelectric focusing
(IEF). If the results were still not clear or indicating the
presence of a rare genotype the genomic DNA was subjected
to sequencing. The testing procedure is summarized in
Fig. 1.
For measurement of the AATamount on the filter paper, a
circular disk was punched out and incubated with 200 ml PBS
overnight at 4 1C. The samples were applied to nephelome-
try (Nephelometer Analyzer 2, Dade Behring, Frankfurt,
Germany) and the result was reported as mg/ml. These data
were not included in the report sent to the physician but
served as internal control.
To detect the S- or Z-allele we used a PCR-based method
that includes the amplification of the two genomic regions
of the Z- and S-allele and the subsequent digestion with a
restriction enzyme that results in a genotype specific
digestion pattern. A circular disk was punched out and
incubated in 1ml aqua dest. After centrifugation in a table
centrifuge, 950 ml of the supernatant were discharged. A
400 ml of 5% solution of Chelix reagent (Sigma Aldrich,
Steinheim, Germany) was added and incubated for 2 h at
56 1C followed by vortexing and heating to 95 1C for 5min. A
5ml was used for a standard PCR reaction applying the
following primers: S-allele, 5-prime: 50-CCT GCC TGA TGA
GGG GAA ACTACA GCA CCT CG-30, 3-prime: 50-GTG TCC ACA
CTG GAG TGG GAA GTT CCC AGG GAC-30; Z-allele, 5-prime:
50-GTG CAT AAG GCT GTG CTG ACC ATC GTC-30, 3-prime: 50-
GCA GGG ACC AGC TCA ACC CTT CTT TAA TG-30 (TIB Molbiol,
Berlin, Germany). We used the REDTag ReadyMix PCR
reaction mix (Sigma Aldrich). The samples were processed
in a MyCycler (Biorad, Munich, Germany). After an initial
denaturation (94 1C, 3min) we applied the following PCR-
conditions for 40 cycles: denaturation at 94 1C for 1min,
annealing at 55 1C for 1min, and extension at 72 1C for
1min. The probes were removed from the PCR machine and
10 ml of Taq I (10 U/ml; Fermentas, St. Leon-Rot, Germany)
were added followed by incubation for 2 h at 65 1C. Then
the samples were subjected to conventional agarose gel
electrophoresis and photographed. The presence of the Z- or
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isons to controls.
IEF was used to analyze samples with suspected mutations
(typical history, low serum level of AAT, presence of the Z- or
S-allele). A circular disk was punched out of the filter paper
and 25 ml aqua dest. were added before incubation overnight
at 4 1C. A polyacrylamide gel was prepared by mixing the
following components: 29.4ml aqua dest., 4.5ml Pharma-
lyte (4.2–4.9, Amersham Biosciences, Freiburg, Germany),
250 ml 10% ammonium persulfate (SERVA Electrophoresis
GmbH, Heidelberg, Germany), 36 ml TEMED (Serva), 7.2ml
Glycerol (Serva), 4.5ml acrylamide/bisacrylamide (29:1,
Serva). A 20 ml of the sample was applied to the gel and
separated using a BlueHorizon horizontal chamber (Serva).
Running conditions were 2500 V, 15mA for 5 h. The gel was
stained with Coomassie Blue and phenotypes were deter-
mined by comparison to various standards.
If the results of the PCR and IEF were not clear or if there
were indications for a rare or unknown genotype, we
requested serum and EDTA-blood. The material was ana-
lyzed together with Dr. Mark Brantly (University of Florida,
Gainesville, Florida, USA) by sequencing of the genomic
DNA. Data on the newly identified mutations of the
SERPINA1 gene will be published separately.
The results were reported to the physician that sent the
material. The report includes the patient identification, and
the outcome of the PCR reaction and the IEF where
applicable. The results letter also included information
how to access further resources about AATD such as the ATS/
ERS guidelines. We also recommended contacting us again if
there were a high degree of clinical suspicion for the
presence of AATD.
All procedures were quality controlled and documented
by standard operating procedures (SOPs). All laboratory
procedures included appropriate negative and positive
controls (different pathological genotypes). The PCR-basedS
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Figure 2 Time line of the detection program. The numbers of kits
points of the activities of the awareness program and the numbers
represent measures of the awareness program and refer to Table 1,
congress. The numbers of kits submitted correlates with the numbe
activities.genetic analysis was controlled by an external interlabora-
tory test.
Results
Global results
As part of our program we offered free genotyping and
phenotyping to diagnose AATD. In the instruction manual we
suggested that the physician measures the blood level of
AAT before submitting the test kit to our laboratory. This
assay is widely available in Germany and inexpensive.
Measurement of the serum level was not included in our
analysis. The testing period started in August 2003. This
retrospective analysis includes data until August 2006
(analysis time 3 years and 1 month). A total number of
17 688 testing kits were distributed on request. We received
a total number of 2722 kits including 603 kits from young
individuals under 20 years and 222 children under 4 years of
age. We identified 335 cases of severe AATD (PiZZ, PiSZ, rare
genotypes). Figure 2 displays the numbers of kits sent out
during the program together with the time line of the
activities of the awareness program and the numbers of test
kits that were received. The number of kits received at the
laboratory correlated with time points of the mailing
activities. Figure 3 summarizes the specialization of the
physicians that sent material to our laboratory.
Test results
A total number of 2696 samples were analyzed. The flow
chart in Fig. 4 summarizes the results of all processed
probes. We identified 335 patients with severe AATD
including 13 persons with known, rare genotypes. In
addition, we identified three novel mutations of the A
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R. Bals et al.1712SERPINA1 locus (results will be published separately). The
testing procedure included the measurement of the amount
of AAT in the dried filter paper as internal control. For most
of the submitted test kits, we did not know whether the AAT
serum level had been determined before sending the kit to
our laboratory. Figure 5 summarized the dependency of the
amount of AAT in the dried filter paper on the genotype
showing that there is a clear cut off threshold thatRequested 
n =17688
•  deficiency ge
•  severe defici
•  MM = 1774
•  MZ = 488
•  MS = 97
•  SZ = 53
•  ZZ = 268
• rare genotype
•  new genotyp
Submitted K
n = 2722
Analysis impossible 
due to missing data or too small 
blood dot 
n = 26
Resu
(12 % of sub
Figure 4 Flow chart explaining the processing of the
Other hospital 
11%
University hospital 
3%
Gastroenterologist 
0%
Pediatrician 
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Figure 3 Medical specializations of the physicians who
submitted test kits to the laboratory.discriminates persons with severe deficiency in most cases.
However, there were five samples with genotypes causing
severe deficiency that showed AAT amounts in the filter
paper above the threshold that had been arbitrarily chosen.
Four out of these samples were obtained from patients on
substitution therapy. Despite this information being knownKits 
Analysis possible
n = 2696
notypes = 930
ency = 332
s = 13
es = 3
its 
lts
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kits and the results of the diagnostic procedure.
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Figure 5 Dependency of the AAT-content in the filter disc on
the genotype. The amount of AAT differed significantly between
the genotypes (as indicated by the bars, Po0.05, ANOVA). Five
persons with PIZZ had results above the arbitrary threshold of
0.7mg/ml. The ends of the boxes define the 25th and 75th
percentiles, with a line at the median and error bars defining
the 10th and 90th percentiles.
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Targeted screening for alpha-1-antitrypsin deficiency 1713before testing we performed the described assays as offered
in our program. Thirty-eight of the samples from individuals
with PiMM revealed a low level of AAT in the dot blot. In
most cases this was due to small amounts of blood applied to
the filter paper. Twenty-six test kits could not be used for
diagnostic testing because of missing consent, missing data
or too little blood.Discussion
The main finding of the present study is that the combina-
tion of an awareness program with a diagnostic test free of
charge results in the identification of a large number of
individuals with severe AATD.
In the current testing program, 8.2% of the submitted test
kits revealed a positive result, i.e. identified an individual
with severe deficiency. The rate of positive results is higher
than in other detection programs. The case detection
program in Spain screened a population of 2137 COPD-
patients and identified eight patients with PiZZ (0.37%).9 A
program in Italy studied 1841 individuals and identified 151
patients with severe deficiency (12%). This study included
persons with clinical suspicion or familial prevalence of
AATD.12 A study in Germany was not able to identify a single
individual with PiZZ in a population of 1060 COPD patients.10
This is in contrast with the present study where 1 in 12
individuals had a severe deficiency type. This discrepancy is
obviously caused by different study populations. The studies
from Wencker et al. 10 and de la Roza et al.9 included
nonselected patients with COPD or other clinical syndromes.
In contrast, our program focused on a population that was
preselected based on clinical suspicion or low serum levels
of AAT. Also the program described by Luisetti et al.12
applied testing to preselected individuals with low serum
levels of AATor early onset emphysema. Table 2 summarizes
the numbers of distributed and returned test kits and the
percentage of severe deficiency phenotypes for these
testing programs. In our testing program we recommended
that the serum level of AAT should be determined as a first
step and that patients are further diagnosed if the serum
level is low or if there is a clinical suspicion. The
measurement of the AAT-concentration in serum is widelyTable 2 Summary of diagnostic rates in AATD detection
programs.
Study (First
author and
reference)
Kits
sent
Kits
returned
% Deficient
genotype
Present study 17688 2722 8.2
Wencker et al.10 1156 1156 0.26
Rodriguez et al.11 72 72 31
Luisetti et al.12 1841 1841 12
De la Roza et al.9 2137 2137 0.37
The studies from Wencker et al., Rodriguez et al., Luisetti et
al., and de la Roza et al. included only those persons that
submitted the testing material. Rodriguez et al. performed a
feasibility study with known number of individuals with PiZZ.available in Germany and offered by almost every clinical
chemistry laboratory. Most of the submitted kits did not
contain information about the serum level. As in other
studies, the amount of AAT detected in the filter paper
correlated well with the serum levels. A cut off could
eventually be used to rule out AATD and to not further
investigate samples with levels above the threshold. We still
performed the analysis including genotyping and in some
cases phenotyping because we specifically offered these
confirmatory tests. Further, we had only limited information
about the patients, the clinical symptoms, or serum AAT
level in most cases. We used the AAT amount in the filter
paper as internal control and to detect patients with the
combination of an M and a rare allele.
Selection of the target population is one critical factor that
determines the detection rate, however, in the present
project the awareness program likely leads to a large number
of submitted test kits. It is well known that the diagnosis of
AATD is hindered by a low level of awareness in the medical
community. AATD is under-recognized with only about 5% of
cases being diagnosed in Europe and in the USA. Also there is
a significant delay of several years between the onset of
symptoms and the diagnosis.6 Even without clear data on the
reasons for this it is obvious that lack of information
contributes. Our awareness program targeted all pulmonary
and pediatric specialists and general practitioners in Germany
by sending a brochure with general information about AATD
and how to access free testing. In addition, we approached
the medical community at national congresses. The distribu-
tion of information material together with the offer of free
testing to a large number of physicians is probably one key
factor for the large number of identified individuals with
AATD. Also a large amount of kits were distributed to ensure a
sufficient supply at the physicians’ offices with only a fraction
sent back to the laboratory.
We detected a surprisingly high number of rare genotypes
and novel genes. Among the subjects with severe AATD we
recorded a 5.7% prevalence of deficient genotypes other
than PiZZ or PiSZ. The NHLBI registry for persons with AATD
with 1021 subjects includes 1.7% individuals with these
criteria.13 The corresponding rate in the Alpha One Founda-
tion Research Network Registry is 5.7%.14 Also a screening
program in Italy had a similar high percentage of individuals
with rare mutations.15
We used a filter paper based test kit for sampling of
blood. This system has several advantages over conventional
collection of serum or blood including simplification of
shipment and the possibility to store the filter paper for
months. Similar systems have been used successfully
before.9–11 We evaluated the results of PCR and IEF
performed on material from the filter paper by comparison
with conventional test specimens and found that both
results are in concordance. The PCR based method was also
controlled in external interlaboratory test. We used the
amount of AAT in the filter paper as internal control. It has
been shown earlier that serum levels correlate well with the
amount of AAT in dried filter papers.10,11 In our study, the
level of AAT highly correlated with the genotype. However,
there were very few patients with PiZZ with AAT levels
above the arbitrary threshold that separates normal serum
levels from deficient. Post-hoc analysis revealed that most
of these individuals were AATD patients already on substitution
ARTICLE IN PRESS
R. Bals et al.1714therapy and that material was submitted for the confirma-
tion of the initial diagnosis. False-positive high AAT levels in
heterozygous individuals could theoretically also be
caused by a coexisting inflammatory process. Some indivi-
duals without any detectable defects in the SERPINA1
locus had low levels of AAT in the filter discs. In most cases
the amount of the blood applied to the filter was very low.
All these cases with low levels were further analyzed
by IEF to exclude rare genotypes. Despite these few samples
with no correlation between genotype and AAT level in the
dot blot, we consider the inclusion of nephelometry
essential. This technique allowed detection of rare geno-
types beyond the Z- or S-allele that would not be detected
by the PCR.
In conclusion, the data show that the combination of an
awareness program with the offer of free diagnostic testing
results in the identification of a large number of individuals
with severe AATD.Acknowledgment
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